The announcement was made in a press release on July 11.
Armata's Board of Directors Chair, Robin C. Kramer, expressed her excitement about Birx joining the team, stating, "As we continue to work to introduce novel phage therapeutics to combat serious bacterial infections, Deborah's expertise in immunology and infectious diseases together with her proven leadership skills will serve us well. I look forward to her contributions as CEO and a member of our Board."
Birx herself expressed her enthusiasm for her new role, saying, "I am thrilled to join Armata at this pivotal time in the Company's development. I'm impressed with the scientific platform's quality and the team's commitment to introducing innovative treatment options for patients suffering from serious bacterial infections. I am excited about the recent advances and see multiple opportunities to accelerate the Company's progress and drive value creation. The recent investment enables the advancement of AP?PA02 and AP?SA02 in Phase 2 clinical trials."
Armata Pharmaceuticals is a California-based clinical-stage biotechnology company that focuses on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. The company is currently developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for various pathogens.
Birx announced her retirement in December 2020, stating her desire for the Biden administration to be successful. She had worked in the federal government since 1980, serving in various roles, including the military, the Department of Health and Human Services, and the State Department. Birx left her position as White House Coronavirus Response Coordinator in January 2021 and resigned from her position as the Coordinator of the United States Government Activities to Combat HIV/AIDS and U.S. Special Representative for Global Health Diplomacy.
In March 2021, Birx became a Senior Fellow at the George W. Bush Presidential Center, where she continues to contribute her expertise. She also joined the board of directors at Innoviva, a diversified holding company with a portfolio of royalties and healthcare investments. Additionally, Birx became a Medical and Science Advisor at ActivePure Technologies, a company dedicated to creating pure indoor spaces.
In September 2022, Birx joined the board of directors for Nanolive, a Swiss microscope company that specializes in breakthrough imaging and analysis solutions for research in growth industries such as drug discovery and cell therapy.
In October 2022, she was named a member of the Federal Advisory Board for Palantir, a software company specializing in data analytics and integration. Palantir's software has been used by various US government agencies, including the CIA, DHS, NSA, FBI, and CDC.
Deborah Birx's extensive experience in public health and infectious diseases makes her a valuable addition to Armata Pharmaceuticals. Her leadership skills and expertise will contribute to the company's mission of developing innovative treatment options for serious bacterial infections. With her new role as CEO, Birx aims to accelerate the company's progress and drive value creation.